RxDoctor Payments Data

Kalpana Hool, MD

Internal Medicine · Torrance, CANPI 1629043799

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 88 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$299
  • Pfizer$219
  • AstraZeneca$188
  • Novo Nordisk$157
  • AbbVie$155
  • Boehringer Ingelheim$150
  • plus $777 from 14 others

What the payments were for

  • Food & beverage$1,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,945 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$241,948
Medicare patients
645
Services billed
2,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$55,840
JardianceEmpagliflozin60$53,347
OzempicSemaglutide49$46,650
RybelsusSemaglutide40$45,756
TradjentaLinagliptin41$37,915
MounjaroTirzepatide35$34,516
JanuviaSitagliptin Phosphate34$32,224
XareltoRivaroxaban26$20,290
JanumetSitagliptin Phos/Metformin Hcl16$15,151
MyrbetriqMirabegron24$14,711
FarxigaDapagliflozin Propanediol18$12,081
Rosuvastatin Calcium440$6,262
SynthroidLevothyroxine Sodium95$5,115
Atorvastatin Calcium416$4,105
Levothyroxine Sodium281$3,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$157$92,40689 claims
Boehringer IngelheimJardiance, Tradjenta$150$91,262101 claims
PfizerEliquis$219$55,84065 claims
MerckJanuvia, Janumet$89$47,37450 claims
Lilly USA, LLCMounjaro$87$34,51635 claims
Astellas Pharma US IncMyrbetriq$21$14,71124 claims
AstraZenecaFarxiga$188$12,08118 claims
AbbVieSynthroid$155$5,11595 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →